675 related articles for article (PubMed ID: 35267040)
41. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
Poh XY; Tan CW; Lee IR; Chavatte JM; Fong SW; Prince T; Hartley C; Yeoh AYY; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim C; Teo J; Lim DRX; Chia W; Hiscox JA; Ng LFP; Ren EC; Lin RTP; Renia L; Lye DC; Wang LF; Young BE
Clin Infect Dis; 2022 Dec; 75(12):2088-2096. PubMed ID: 35543372
[TBL] [Abstract][Full Text] [Related]
42. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
43. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
[TBL] [Abstract][Full Text] [Related]
44. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
[TBL] [Abstract][Full Text] [Related]
45. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
[TBL] [Abstract][Full Text] [Related]
46. Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.
Leung NHL; Cheng SMS; Martín-Sánchez M; Au NYM; Ng YY; Luk LLH; Chan KCK; Li JKC; Leung YWY; Tsang LCH; Chaothai S; Kwan KKH; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Cowling BJ
Clin Infect Dis; 2023 Feb; 76(3):e299-e307. PubMed ID: 35675370
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Klinfueng S; Sudhinaraset N; Poovorawan Y
Vaccine; 2022 May; 40(23):3203-3209. PubMed ID: 35465981
[TBL] [Abstract][Full Text] [Related]
48. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
[TBL] [Abstract][Full Text] [Related]
49. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
[TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine.
Chaiwarith R; Winichakoon P; Salee P; Sudjaritruk T; Wipasa J; Chawansuntati K; Yasri S; Thongwitokomarn H; Krasaewes K; Ruangsirinusorn S; Praparattanapan J; Solai N; Nuket K; Boonmee D; Chaichana O; Mueangmo O; Saheng J; Wongjak W
Sci Rep; 2023 Nov; 13(1):19736. PubMed ID: 37957189
[TBL] [Abstract][Full Text] [Related]
51. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.
Ling TC; Chen PL; Li NY; Ko WC; Sun CY; Chao JY; Shieh CC; Shen CF; Wu JL; Huang TC; Chao CH; Wang JR; Chang YT
Microbiol Spectr; 2023 Feb; 11(2):e0344522. PubMed ID: 36809164
[TBL] [Abstract][Full Text] [Related]
52. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA
Front Immunol; 2022; 13():882918. PubMed ID: 35958601
[TBL] [Abstract][Full Text] [Related]
53. Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
Kong W; Zhong Q; Chen M; Yu P; Xu R; Zhang L; Lai C; Deng M; Zhou Q; Xiong S; Liang Y; Wan L; Lin M; Wang M; Mai W; Chen L; Lei Y; Qin N; Zhu J; Ruan J; Huang Q; Kang A; Wang J; Li W; Ji T
J Med Virol; 2023 Jan; 95(1):e28163. PubMed ID: 36127294
[TBL] [Abstract][Full Text] [Related]
54. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
56. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
Li J; Hou L; Guo X; Jin P; Wu S; Zhu J; Pan H; Wang X; Song Z; Wan J; Cui L; Li J; Chen Y; Wang X; Jin L; Liu J; Shi F; Xu X; Zhu T; Chen W; Zhu F
Nat Med; 2022 Feb; 28(2):401-409. PubMed ID: 35087233
[TBL] [Abstract][Full Text] [Related]
57. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
58. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations.
Jacobsen H; Strengert M; Maaß H; Ynga Durand MA; Katzmarzyk M; Kessel B; Harries M; Rand U; Abassi L; Kim Y; Lüddecke T; Metzdorf K; Hernandez P; Ortmann J; Heise JK; Castell S; Gornyk D; Glöckner S; Melhorn V; Kemmling Y; Lange B; Dulovic A; Marsall P; Häring J; Junker D; Schneiderhan-Marra N; Hoffmann M; Pöhlmann S; Krause G; Cicin-Sain L
Sci Rep; 2022 Nov; 12(1):19858. PubMed ID: 36400804
[TBL] [Abstract][Full Text] [Related]
59. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
60. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
Rammauro F; Carrión F; Olivero-Deibe N; Fló M; Ferreira A; Pritsch O; Bianchi S
Vaccine; 2022 Aug; 40(35):5189-5196. PubMed ID: 35907676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]